La UE autoriza venta de remdesivir contra coronavirus

BRUXELLES, Bélgica. La Comisión Europea autorizó provisionalmente este viernes la venta del medicamento antiviral remdesivir para el tratamiento de pacientes con coronavirus en la Unión Europea (UE), después del visto bueno de la Agencia Europea de Medicamentos.

(FILES) This file photograph taken on April 8, 2020, shows a vial of the drug 'remdesivir' during a press conference concerning the start of a study with the Ebola drug to treat severely ill patients afflicted with coronavirus COVID-19, at The University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the global pandemic. - The European Medicines Agency said June 25, 2020, that it has recommended authorising the use of anti-viral drug remdesivir to treat the new coronavirus. "Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU," the agency said, adding that the recommendation still needs approval from the European Commission. (Photo by Ulrich Perrey / POOL / AFP)
(FILES) This file photograph taken on April 8, 2020, shows a vial of the drug 'remdesivir' during a press conference concerning the start of a study with the Ebola drug to treat severely ill patients afflicted with coronavirus COVID-19, at The University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the global pandemic. - The European Medicines Agency said June 25, 2020, that it has recommended authorising the use of anti-viral drug remdesivir to treat the new coronavirus. "Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU," the agency said, adding that the recommendation still needs approval from the European Commission. (Photo by Ulrich Perrey / POOL / AFP)ULRICH PERREY

El ejecutivo comunitario concedió “una autorización de comercialización condicional para el medicamento remdesivir, convirtiéndolo en el primer medicamento autorizado a nivel de la UE para el tratamiento de la COVID-19”, anunció en un comunicado.

PUBLICIDAD

Te puede interesar

PUBLICIDAD
PUBLICIDAD